Products Entecavir + Lamivudine + Pegylated Interferon Alfa-2A
Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Phase 3 Completed 📈 Rising Pediatric Immuno-Tolerant Chronic Hepatitis B
Pediatric Immuno-Tolerant Chronic Hepatitis B
Jun 16, 2014 → Jan 29, 2020
About Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Entecavir + Lamivudine + Pegylated Interferon Alfa-2A is a phase 3 stage product being developed by Roche for Pediatric Immuno-Tolerant Chronic Hepatitis B. The current trial status is completed. This product is registered under clinical trial identifier NCT02263079. Target conditions include Pediatric Immuno-Tolerant Chronic Hepatitis B.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02263079 Phase 3 Completed Jun 16, 2014 Jan 29, 2020 Pediatric Immuno-Tolerant Chronic Hepatitis B
Competing Products 20 competing products in Pediatric Immuno-Tolerant Chronic Hepatitis B
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3
Other Products from Roche